Download Files:
Navoximod
$198 – $1,400
Products Details
Product Description
– Navoximod (GDC-0919; NLG-919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
Web ID
– HY-18770B
Storage Temperature
– -20°C (Powder, stored under nitrogen)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C18H21FN2O2
References
– [1]Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.|[2]Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.|[3]Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.
CAS Number
– 1402837-78-8
Molecular Weight
– 316.37
Compound Purity
– 99.99
SMILES
– O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Indoleamine 2,3-Dioxygenase (IDO)
Isoform
– IDO
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
